Electric fields + chemo + radiation: a new attack on brain cancer?

NCT ID NCT04474353

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a combination of tumor treating fields (a device that creates electric fields to disrupt cancer growth), stereotactic radiosurgery (precise radiation), and temozolomide chemotherapy in 12 adults with newly diagnosed glioblastoma. The main goal was to see if the combination is safe and to identify any severe side effects. The study is complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor treating fields (TTFields) device, temozolomide chemotherapy, and stereotactic radiosurgery
What this could lead to: If successful, this combination could offer a new way to control glioblastoma, potentially extending survival with manageable side effects.
What could go wrong: This is a very early phase 1 trial with only 12 people, so it's mainly checking safety, not effectiveness. The treatment may not work better than standard care and could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA NEWLY DIAGNOSED GLIOBLASTOMA

Contacts and locations

Locations

Stanford University

Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.